{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-246234","form_type":"8-K","ticker":"TNGX","cik":"0001819133","company_name":"Tango Therapeutics, Inc.","filed_at":"2021-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:04:19.833056+00:00","generated_at":"2026-06-29T11:44:43.196189+00:00","sec_items":["1.01","2.01","9.01","3.02","3.03","4.01","5.01","5.02","5.03","5.05","5.06","5.07"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Tango Therapeutics completes de-SPAC merger; starts trading on Nasdaq under TNGX","bullets":["Merger closed Aug 10, 2021; Old Tango shares converted at ~0.34 share of new common stock per share.","PIPE investors purchased 18.61M shares at $10.00/share, raising $186.1M in gross proceeds.","Post-merger, 87,474,258 shares of common stock outstanding and 9,498,725 shares subject to equity awards.","Common stock began trading on Nasdaq Capital Market on Aug 11, 2021 under ticker TNGX.","Directors and officers entered into lock-up agreements for 180 days after closing."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-246234","json":"https://secwatch.observer/filing/0001193125-21-246234.json","markdown":"https://secwatch.observer/filing/0001193125-21-246234.md","text":"https://secwatch.observer/filing/0001193125-21-246234.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819133/000119312521246234/0001193125-21-246234-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819133/000119312521246234/d203347d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T11:44:43.196189+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"03f56a4701","claim":"Lesley Calhoun was appointed as Director at Tango Therapeutics, Inc..","evidence_excerpt":"Lesley Calhoun and Reid Huber were appointed as Class I directors, Malte Peters and Mace Rothenberg were appointed as Class II directors and Alexis Borisy, Aaron Davis and Barbara Weber were appointed as Class III directors.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312521246234/0001193125-21-246234-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"600b43ef4d","claim":"Mace Rothenberg was appointed as Director at Tango Therapeutics, Inc..","evidence_excerpt":"Lesley Calhoun and Reid Huber were appointed as Class I directors, Malte Peters and Mace Rothenberg were appointed as Class II directors and Alexis Borisy, Aaron Davis and Barbara Weber were appointed as Class III directors.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312521246234/0001193125-21-246234-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"74e92f7c58","claim":"Aaron Davis was appointed as Director at Tango Therapeutics, Inc..","evidence_excerpt":"Lesley Calhoun and Reid Huber were appointed as Class I directors, Malte Peters and Mace Rothenberg were appointed as Class II directors and Alexis Borisy, Aaron Davis and Barbara Weber were appointed as Class III directors.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312521246234/0001193125-21-246234-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"7b81666c6d","claim":"Alexis Borisy was appointed as Director at Tango Therapeutics, Inc..","evidence_excerpt":"Lesley Calhoun and Reid Huber were appointed as Class I directors, Malte Peters and Mace Rothenberg were appointed as Class II directors and Alexis Borisy, Aaron Davis and Barbara Weber were appointed as Class III directors.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312521246234/0001193125-21-246234-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"8779f10849","claim":"Malte Peters was appointed as Director at Tango Therapeutics, Inc..","evidence_excerpt":"Lesley Calhoun and Reid Huber were appointed as Class I directors, Malte Peters and Mace Rothenberg were appointed as Class II directors and Alexis Borisy, Aaron Davis and Barbara Weber were appointed as Class III directors.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312521246234/0001193125-21-246234-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"d40e8f1a58","claim":"Barbara Weber was appointed as Director at Tango Therapeutics, Inc..","evidence_excerpt":"Lesley Calhoun and Reid Huber were appointed as Class I directors, Malte Peters and Mace Rothenberg were appointed as Class II directors and Alexis Borisy, Aaron Davis and Barbara Weber were appointed as Class III directors.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312521246234/0001193125-21-246234-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"e73299678e","claim":"Reid Huber was appointed as Director at Tango Therapeutics, Inc..","evidence_excerpt":"Lesley Calhoun and Reid Huber were appointed as Class I directors, Malte Peters and Mace Rothenberg were appointed as Class II directors and Alexis Borisy, Aaron Davis and Barbara Weber were appointed as Class III directors.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312521246234/0001193125-21-246234-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}